All In Biotech

Drug Trial Radar · NCT07941206

A Phase 1b Study of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder Caused by Non-Gain-of-Function Variants

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 1b Study With an Open-Label Extension to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-Function

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Oct 2027

Study completion Dec 2027

Sponsor

Lead sponsor
GRIN Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multinational, multicenter, randomized, double-blinded, placebo-controlled, Phase 1b study with an open-label extension (OLE) to assess safety, tolerability, PK, and potential efficacy of radiprodil for the treatment of GRIN-related neurodevelopmental disorder (GRIN-NDD) in children with a genetic variant characterized as non-gain-of-function. This study will consist of Part A (blinded, placebo-controlled) and Part B (blinded transition followed by an OLE). Participants will be randomized in a 2:1 ratio to receive active drug (radiprodil) or matching placebo (Part A) and stratified by functional characterization (either indeterminant, LoF, or no effect). Following completion of Part A, all eligible participants (including those previously on placebo) may continue into the open-label extension period (Part B) to receive radiprodil. The placebo-controlled portion is expected to be approximately 17 weeks for participants in Part A and at least 12 months for participants in Part B.

Conditions

  • GRIN-related Neurodevelopmental Disorder Caused by Variants Characterized as Non-Gain-of-Function

Interventions

  • RadiprodilDrug

    Radiprodil oral suspension

  • PlaceboDrug

    Placebo-to-match radiprodil oral suspension

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AEs)Time frame: From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).
  2. Serious Adverse Events (SAEs)Time frame: From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).
  3. Adverse Drug Reactions (ADRs)Time frame: From Screening through study completion, including Part A (approximately 17 weeks), Part B (anticipated at least 12 months), and follow-up (14 [+7] days after the last dose including taper or End of Study Visit, whichever is later).
  4. Change From Baseline in Blood PressureTime frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
  5. Change From Baseline in Pulse RateTime frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
  6. Physical Examination FindingsTime frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
  7. Change From Baseline in ECG Pulse RateTime frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
  8. Change From Baseline in ECG RR IntervalTime frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
  9. Change From Baseline in ECG PR IntervalTime frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
  10. Change From Baseline in ECG QRS DurationTime frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
  11. Change From Baseline in ECG QT IntervalTime frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
  12. Change From Baseline in ECG QTcF IntervalTime frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
  13. Clinically Significant Changes in Clinical Laboratory ParametersTime frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
  14. Emergence of New Seizure TypesTime frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
  15. Occurrence of Suicidal IdeationTime frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).
  16. Occurrence of Suicidal BehaviorTime frame: From Baseline through study completion, including Part A (approximately 17 weeks) and Part B (anticipated at least 12 months).

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.